Allscripts announces Veradigm AccelRx™ to help reduce patient wait times for specialty medications
March 04 2020 - 8:01AM
Business Wire
Solution simplifies complex path to Rx
fulfillment
Allscripts Healthcare Solutions (NASDAQ:MDRX) has unveiled a
unique new software solution for specialty medication management,
delivered by Veradigm™, its business unit focused on payer and life
sciences.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200304005064/en/
Veradigm’s AccelRx™ is designed to simplify meeting the
requirements needed to dispense the increasing number of specialty
medications being prescribed. AccelRx leverages broad industry
partnerships built over decades of e-prescribing and prior
authorization to deliver a user-friendly solution that is helping
providers spend less time on phone calls and managing faxes while
driving higher patient medication adherence.
Despite representing only 3% of all prescriptions written in the
U.S., in 2020, specialty medications are expected to account for up
to 50% of the total spend on prescription medications. For a
specialty medication prescription to be filled, it must pass
through a broad cross-section of healthcare stakeholders, including
payers, specialty pharmacies and specialty Rx hubs. The result can
be extended patient wait times.
“AccelRx is another example of Veradigm spanning the healthcare
ecosystem to find mutually beneficial ways for key stakeholders to
work together and to improve patient care,” said Tom Langan, CEO of
Veradigm. “By delivering a solution that can automate and simplify
the complex series of reviews required to fill a specialty
prescription, we believe we can help a broad group of healthcare
providers to reduce the time it takes to get these medications to
patients.”
Combining one of healthcare’s largest prescriber bases with
broad industry partnerships built over decades of e-prescribing and
prior authorization leadership, Veradigm AccelRx delivers a
solution designed to streamline specialty medication fulfillment
and reduce patient wait times.
“There is a growing number of patients affected by the extended
delays in receiving their prescribed specialty medications, and
it’s a challenge for many segments of the healthcare market
including patients and providers,” said Paul Black, Allscripts
Chief Executive Officer. “That’s why it is so important to be part
of the solution to address this growing need.”
As the impact of specialty medications on healthcare in the U.S.
continues to grow, so does the number of patients and providers who
can benefit from the value AccelRx provides. As a result, Veradigm
is actively engaged in developing ongoing partnerships with key
healthcare industry stakeholders to continue expanding the scope of
sophistication of the AccelRx solution throughout 2020 and beyond.
For more information, visit www.veradigm.com/accelrx.
About Veradigm™
Veradigm is an integrated data systems and services company that
combines data-driven clinical insights with actionable tools to
help healthcare stakeholders improve the quality, efficiency, and
value of healthcare delivery— including biopharma, health plans,
healthcare providers, health technology partners, and most
importantly, the patients they serve. We are dedicated to
simplifying the complicated healthcare system with next-generation
healthcare solutions. This is how we are transforming health,
insightfully. To learn more, visit www.veradigmhealth.com.
About Allscripts
Allscripts (NASDAQ: MDRX) is a leader in healthcare information
technology solutions that advance clinical, financial and
operational results. Our innovative solutions connect people,
places and data across an Open, Connected Community of Health™.
Connectivity empowers caregivers to make better decisions and
deliver better care for healthier populations. To learn more, visit
www.allscripts.com, Twitter, YouTube and It
Takes A Community: The Allscripts Blog.
© 2020 Allscripts Healthcare, LLC and/or its affiliates. All
Rights Reserved. Allscripts, the Allscripts logo, and other
Allscripts marks are trademarks of Allscripts Healthcare, LLC
and/or its affiliates. All other products are trademarks of their
respective holders, all rights reserved. Reference to these
products is not intended to imply affiliation with or sponsorship
of Allscripts Healthcare, LLC and/or its affiliates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200304005064/en/
For more information contact:
Investors: Stephen Shulstein
312-386-6735 Stephen.Shulstein@allscripts.com
Media: Concetta Rasiarmos
312-447-2466 concetta.rasiarmos@allscripts.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Sep 2023 to Sep 2024